Frontier capability keeps getting cheaper and reaches deeper into personal data, even as investors start questioning who pays for the build-out.
Cheaper frontier models, generative AI moving into medical data, and a market growing sceptical about the returns on hyperscaler infrastructure spending.
Effective price cuts at the top of the market keep lowering the cost of putting high-end AI to work, and that makes tool-selection decisions for coding and knowledge work worth revisiting.
Generative AI is moving in earnest into sensitive personal medical data, adding privacy and data-governance questions to any AI service review.
The market is nervous about whether vast AI infrastructure investment pays back, raising the bar for return-on-investment accountability in your own AI plans and vendor choices.
Frontier AI companies keep competing on effective price cuts for high-performance models, Claude Opus 5 among them.
Generative AI is integrating in earnest with sensitive everyday domains such as personal medical data.
Market scepticism is intensifying over the return on hyperscalers' enormous AI capital spending.
Capability per unit of cost is improving fast enough to date last quarter's evaluation, while the market demands sharper evidence that the spending behind it earns a return.
Earnings from Microsoft, Meta and Amazon, whose capital-spending plans the market was already braced for when this week's selling began.